SEC filings

2022

• June 2, 2022 6-K, "Pharming Group to present at Jefferies Healthcare Conference 2022"

• May 18, 2022 6-K, "Pharming Group: all proposals Annual General Meeting of Shareholders approved"

• May 12, 2022 6-K "Pharming Group reports financial results for the first quarter of 2022"

• May 5, 2022 6-K "Pharming Group Notice of Q1 Results"

• April 22, 2022 6-K "Pharming announces change in its holding in BioConnection following a substantial investment by new investor"

• April 6, 2022 6-K "Pharming announces the filing of its 2021 Annual Report, with Form 20-F also filed with the U.S. Securities and Exchange Commission and convenes its 2022 AGM"

• February 2, 2022 6-K "Pharming announces positive results of Phase II/III pivotal clinical study of leniolisib for the treatment of activated PI3K delta syndrome"

• January 6, 2022 6-K "Pharming receives positive EMA decision on paediatric investigation plan (PIP) for leniolisib in Europe"

• January 4, 2022 6-K "Pharming Group and Sanofi renew strategic manufacturing partnership agreement"

2021

• October 28, 2021 6-K "Pharming Group reports financial results for the first nine months of 2021"

• October 22, 2021 6-K "Pharming Group Notice of 9M Results"

• September 14, 2021 6-K "Pharming announces results from clinical trials for the treatment of COVID-19 with RUCONEST®"

• August 5, 2021 6-K "Pharming Group reports financial results for the first half of 2021"

• July 20, 2021 6-K "Pharming signs agreement with NewBridge Pharmaceuticals for the commercialization of RUCONEST® in the Middle East and North Africa"

• July 1, 2021 6-K "Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo HSC Gene Therapy for Hereditary Angioedema"

• June 23, 2021 6-K ''Pharming announces completion of enrolment in Phase II/III study with leniolisib for activated PI3K delta syndrome''

• June 18, 2021 6-K ''Pharming appoints Anurag Relan as Chief Medical Officer and Robert Friesen as Chief Scientific Officer''

• June 4, 2021 6-K ''Pharming Group N.V. announces the reimbursement of RUCONEST® in Spain''

• June 1, 2021 6-K ''Pharming Group to present at Jefferies Virtual Healthcare Conference''

• May 19, 2021 6-K ''Pharming Reports on Annual General Meeting of Shareholders''

• May 13, 2021 6-K "Pharming Group reports financial results for the first quarter of 2021"

• April 22, 2021 6-K ''Pharming announces enrollment of first patient in multicenter Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarction''

• April 7, 2021 20-F "2020 Annual report on Form 20-F submitted to the U.S. Securities and Exchange Commission"

• April 7, 2021 6-K "Pharming Group announces the filing of its 2020 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission"

• April 6, 2021 6-K ''Pharming Group announces the publication of its 2020 Annual Report and convenes its 2021 AGM''

• March 23, 2021 6-K "Pharming Group announces the intention to nominate three Non-Executive Directors to the Board of Directors"

• March 16, 2021 6-K "Pharming Group to present at 31st Annual Oppenheimer Healthcare"

• March 11, 2021 6-K "Pharming Group to Present at BioCapital Europe 2021" 

• March 4, 2021 6-K "Pharming Group reports financial results for full year 2020" 

• March 2, 2021 6-K "Pharming Group, in collaboration with Invitae Corporation, launches genetic testing program ‘navigateAPDS’"

2020

• December 22, 2020 6-K: "Pharming Group announces ADSs admitted to trade on Nasdaq under the symbol “PHAR”"

• December 22, 2020 6-K: "Pharming Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq Listed ADSs Costs for conversion of Ordinary Shares into ADS’s waived by JP Morgan Chase for initial four weeks after today"

• December 22, 2020 F-1 Registration Statement

To view all Company SEC filings please visit the SEC's website here: https://sec.report/T/PHAR